Fig. 4.

Distribution of expenditure across healthcare modalities during the 3 years before and after initiation of DPP4I therapy in a the DPP4I monotherapy group (n = 79), b the DPP4I combined with another OAD without insulin group (n = 709), and c the DPP4I combined with insulin (n = 131) group. DPP4I dipeptidyl peptidase 4 inhibitor, OAD oral antidiabetic, y year(s), n1–n3 number of patients who continued DPP4I therapy 1–3 years after initiation. Other ambulatory care covers all other costs, such as spa care, partially or totally reimbursed by the French national healthcare scheme